Vitiligo Patients Research Articles

Clinical patterns of vitiligo in Japan: A descriptive study using the JMDC claims database.

Vitiligo is a chronic autoimmune disorder that profoundly impacts patients' quality of life. Real-world data on vitiligo in Japan are limited. This descriptive, cross-sectional study used a claims database to evaluate vitiligo prevalence, patient demographics, treatments, and comorbidities in Japanese patients with vitiligo. Patients with claims for a vitiligo diagnosis in the JMDC database from January 2010 to December 2022 were included. Annual vitiligo prevalence, comorbidities, treatments, and medical facility visits were analyzed. Of 16 947 087 patients in the database during the 13-year analysis period, a total of 26 358 patients (0.16%, 95% confidence interval 0.15-0.16) had a diagnosis of vitiligo. The standardized prevalence of vitiligo by sex and age in Japan remained generally consistent between 2010 (0.051%) and 2022 (0.056%). Atopic dermatitis was the most prevalent comorbidity. Comorbid atopic dermatitis prevalence increased between 2010 (21.8%) and 2022 (34.0%), and was highest among children aged 5-9 years. Other common comorbidities in 2022 included hypertension (10.4%), dyslipidemia (8.0%), anxiety disorder (7.4%), and psoriasis (7.0%). Topical corticosteroids were the most commonly used treatment throughout the period analyzed. Between 2010 and 2022, topical corticosteroid use decreased from 75.1% to 66.9%, and the use of narrowband ultraviolet B procedures increased from 19.2% to 28.1%. Mean duration of care was 12.9 months (standard deviation 20.5 months) and the median total number of outpatient medical facility visits was 3.0 (interquartile range 1.0-12.0). Key limitations include age and occupational biases in the JMDC database and potential misclassification of comorbidities due to off-label treatment coding. Despite limitations in using a claims database, this study demonstrates consistent vitiligo prevalence in Japan, a high comorbidity burden, and evolving treatment patterns. Findings may guide clinical practice and treatment guidelines to improve management of vitiligo in Japanese patients.

Evaluation of the serum level of Lipocalin 2 in vitiligo.

Vitiligo is considered as depigmenting skin disorder where patches of skin losing their pigment. Lipocalin-2 (LCN2) is one of the Inflammatory adipokines that has a potential role in skin disorders and other inflammatory diseases as well. To measure the concentration level of LCN2 in vitiligo patients compared to healthy controls and to investigate its relation to disease activity and other clinical data to evaluate its role in the pathogenesis of the disease. Eighty individuals subdivided equally into two groups (vitiligo and controls) were enrolled in the study. The serum level of LCN2 was measured by ELISA where from all participants, a 5-mL venous blood was withdrawn in plain tube from each subject. There were high significant difference of LCN2 in serum between both groups where LCN2 was higher in vitiligo patients than than controls with mean and standard deviations of 399.2 ± 134.6 and 257.2 ± 42.5 respectively (p < 0.001). The level of LCN2 tended to increase in vitiligo patients with sudden onset than gradual patients showing a significant difference with p-value 0.030. Regarding the severity of the disease results showed that the level of LCN2 tended to increase in moderate and severe patients than mild but with no significant difference between the groups. LCN2 may play a vital role and a good marker for the early diagnosis and the pathogenesis of vitiligo disease.

Ritlecitinib, a JAK3 /TEC inhibitor, modulates the markers of celiac autoimmunity in alopecia areata and vitiligo patients

Ritlecitinib, a JAK3 /TEC inhibitor, modulates the markers of celiac autoimmunity in alopecia areata and vitiligo patients

Integrative genetics and multiomics analysis reveal mechanisms and therapeutic targets in vitiligo highlighting JAK STAT pathway regulation of CTSS

Vitiligo is a complex autoimmune disease characterized by the loss of melanocytes, leading to skin depigmentation. Despite advances in understanding its genetic and molecular basis, the precise mechanisms driving vitiligo remain elusive. Integrating multiple layers of omics data can provide a comprehensive view of disease pathogenesis and identify potential therapeutic targets. The study aims to delineate the genetic and molecular mechanisms of vitiligo pathogenesis using an integrative multiomics strategy. We focus on exploring the regulatory influence of the JAK/STAT pathway on Cathepsin S, a potential therapeutic target in vitiligo. Our GWAS-meta analysis pinpointed five druggable genes: ERBB3, RHOH, CDK10, MC1R, and NDUFAF3, and underwent drug target exploration and molecular docking. SMR analysis linked CTSS, CTSH, STX8, KIR2DL3, and GRHPR to vitiligo through pQTL and eQTL associations. Microarray and single-cell RNA-seq data showed differential expression of CTSS and STAT1/3 in vitiligo patients’ blood and skin lesions. Our study offers novel perspectives on vitiligo’s genetic and molecular basis, highlighting the JAK/STAT pathway’s role in regulating CTSS for antigen processing in melanocytes. Further research is needed to confirm these results and assess the therapeutic potential of CTSS and related genes.

Fractional CO2 laser combined with narrow-band ultraviolet B (NB-UVB) phototherapy versus NB-UVB monotherapy in vitiligo patients: prospective, self-controlled, and randomized trial.

Vitiligo is a chronic depigmenting condition that causes amelanotic macules and patches on the skin. Despite various treatment options, treating vitiligo is a challenge. This study aimed to evaluate the combination of laser CO2 fractional and narrow-band ultraviolet B (NB-UVB) versus NB-UVB monotherapy in vitiligo patients. This was a prospective, self-controlled, and randomized trial. Ten patients with symmetrical vitiligo lesions on both sides of their body and who had a history of insufficient response to conventional therapies were included in this trial. Group A received three sessions of fractional CO2 laser at 1-month intervals during NB-UVB phototherapy which was performed three times a week for three months. Patients in group B only received phototherapy same as group A. The primary endpoint was the repigmentation rate. The mean age was 34.40 ± 11.93 years (range of 19-63). After the intervention, repigmentation was better in group A and the difference was statistically significant (P = 0.025). Patients in group A showed a better reduction of VASI score than group B (39.12 ± 27.81 Vs. 44.45 ± 30.77), although it was not statistically significant (P = 0.518). VETF and VIDA outcomes were slightly better in Group A than B, but it was not statistically significant (P = 0.317 and P = 0.180, respectively). The results of this study indicated that combining fractional CO2 laser with NB-UVB is superior to NB-UVB monotherapy, providing a promising modality in vitiligo patients.

Characteristics of Vitiligo Patients in Dermatology and Venereology Outpatient Clinic Unit at Bali Mandara General Hospital 2021-2022

Vitiligo is a depigmentation disorder characterized by the distinct macules or depigmented patches, which are often asymptomatic. Age and geographic location have an impact on the prevalence of vitiligo. This condition affects 0.5-2% of the global population and is caused by a combination of factors, including clinical symptoms and therapeutic outcomes. Methods: The research material was taken from the medical record of vitiligo patients in the Outpatient Clinic Dermatovenerelogy Bali Mandara General Hospital from 2021-2022. The data were analyzed descriptively using SPSS program version 26 for Windows. Result: This study collected 198 visits from vitiligo patients at the Bali Mandara General Hospital Dermatovenereology outpatient clinic. The predominant gender is female (55.1%), with late adolescents comprising 36.4%, students accounting for 38.4%, and the development of vitiligo occurring within 1-5 years for 54% of cases; 63.1% of patients lacked a familial history of vitiligo. The predominant clinical kind is non-segmental vitiligo (59.1%), and the most frequently used treatment is excimer light phototherapy (85.9%). Conclusion: Vitiligo patients at Bali Mandara hospital, Denpasar, mostly female aged 17-25 years old, with non-segmental vitiligo . The most common therapies given are excimer light phototherapy.

Comorbidities Associated with Vitiligo: Results from the EpiChron Cohort.

Background: Vitiligo is a pigmentation disorder that impacts approximately 0.5% to 2% of the global population. Growing interest surrounds the comorbidities associated with vitiligo. This study aimed to describe the socio-demographic characteristics of the patients with vitiligo in Aragón (Spain) and to investigate their associated comorbidities. Methods: A retrospective observational study was conducted using clinical data from individuals in the EpiChron Cohort (reference population of 1.3 million) who were diagnosed with vitiligo between 1 January and 31 December 2019. The prevalence of chronic comorbidities was calculated using logistic regression models, obtaining the odds ratio (OR) of each comorbidity (dependent variable) according to the presence or absence of vitiligo (independent variable). We used a cut-off point for a statistical significance of p-value < 0.05. Results: In total, 218 patients diagnosed with vitiligo were analyzed. The mean age was 44.0 years, and 56.42% were female. The largest proportion of patients (34.86%) were aged between 18 and 44 years. Among all vitiligo patients included, 71.5% presented multimorbidity, with an average of 3.21 diagnosed comorbidities. The conditions most frequently associated with vitiligo included thyroid disorders (OR: 3.01, p < 0.001), ocular and hearing abnormalities (OR: 1.54, p < 0.020), inflammatory skin disorders (OR: 2.21, p < 0.001), connective tissue diseases (OR: 1.84, p < 0.007), lower respiratory tract diseases (OR: 1.78, p < 0.014), urinary tract infections (OR: 1.69, p < 0.032), and cardiac arrhythmias (OR 1.84, p < 0.034). Conclusions: This research highlights the importance of understanding the broader health implications of vitiligo and provides a foundation for further exploration into the complex interplay between this dermatologic condition and a diverse range of comorbidities.

The role of serum S100B and serum thyroid stimulating hormone levels in vitiligo.

Vitiligo is a depigmenting disorder characterized by melanocyte loss, which results in pigment dilution of the skin. Vitiligo is commonly associated with thyroid disorders and thyroid stimulating hormone (TSH) is a sensitive marker to detect thyroid disorders. S100B is damage associated molecular pattern (DAMP) molecule released when there is melanocyte damage. In this study, we are estimating the serum TSH and S100B levels in vitiligo patients and controls and correlating them with disease activity. A cross-sectional study was conducted on 39 cases of vitiligo and controls. Demographic details were collected, the cases were examined and Vitiligo European Task Force (VETF) scoring was performed. Serum S100B was analyzed using an ELISA kit and serum TSH levels were estimated. Age of the participants ranged from 14 to 81 years with a mean and standard deviation of 44.08 ± 16.078 years. Female preponderance was noted. Vitiligo vulgaris was the most common presentation. Serum TSH (p = 0.32) and S100B (p = 0.22) levels between cases and controls were not statistically significant. Serum S100B level had a weak positive correlation with the spreading component of VETF score and it was statistically significant (p = 0.004). Mucosal vitiligo had higher levels of serum S100B levels compared to other types of vitiligo. In our study both serum TSH and S100B levels have demonstrated limited utility in distinguishing between vitiligo patients and controls. S100B showed a weak correlation with VETF scores indicating its potential (though limited) as a disease activity marker. Therefore, the potential of using this as a biomarker is debatable, and further multicentric studies with a larger sample size are required to establish the correlation.

Mapping the vitiligo patient journey: from awareness to treatment or coping strategies.

Mapping the vitiligo patient journey: from awareness to treatment or coping strategies.

Safety and efficacy of tacrolimus ointment alone in the treatment of pediatric vitiligo: A systematic review and meta-analysis

Introduction: Vitiligo, a skin disorder affecting melanocytes, poses treatment challenges. There is a need to investigate the role of Tacrolimus in pediatric cases for its efficacy and safety. The present study aims to assess the safety and efficacy of tacrolimus ointment in treating pediatric vitiligo patients. Methods: A review study was conducted and a literature search was done on 2nd August 2023, by using the words "vitiligo" and "tacrolimus" through five databases including PubMed. We found 8 studies from 930 records. Results: The rates of excellent, moderate, mild, minimal improvement, and no response were 29% (95%CI: 16-47), 26% (95%CI: 19-35) 28% (95%CI: 20-37), 19% (95%CI: 12-29) and 8% (95%CI: 2-25). No systemic side effects were reported. The overall prevalence of local side effects was 14% (95%CI: 7-24). Burning sensation prevalence was 11% (95%CI: 7-18) while pruritus prevalence was 9% (95%CI: 2-33). Study limitations encompassed varied vitiligo sites, patient demographics, and follow-up durations, lacked comparative treatment data, and necessitated further research on combined therapies, especially in pediatric cases. Conclusion: Tacrolimus showed good efficacy regarding the re-pigmentation improvement in pediatric vitiligo patients. Furthermore, no systemic side effects were reported and local side effects were minimal mainly in the form of a burning sensation and pruritis.

Investigation of the Prevalence of Depressive Illness in Vitiligo Patients: A Cross-sectional Study

Background Vitiligo, as a progressive skin disease, is associated with the public's negative attitudes toward this condition, as well as numerous social and familial problems that can lead to psychiatric disorders. Aim The present study was conducted to determine the frequency of depressive illness in patients with vitiligo. Methods This is a cross-sectional descriptive study conducted using census sampling on 178 patients with vitiligo who were referred to the skin clinic of Imam Khomeini Hospital (RA) in Jiroft in 2023. Data were collected face-to-face using the Beck Depression Questionnaire and analyzed using descriptive and inferential statistical tests in SPSS-22 statistical software, with a significance level of p less than 0.05. Results The average age of the examined patients was 31.4 ± 6.8 years. Of the participants, 53.3% were women and 46.7% were men. The frequency of individuals exhibiting moderate and severe depressive symptoms was 17.9% and 28.8%, respectively. The prevalence of depressive illness was higher among married women compared to single women. Conclusion The high prevalence of depressive illness symptoms in these patients underscores the urgent need for effective interventions and treatment strategies to address this mental health concern. The findings of this study highlight the necessity for continuous surveillance and monitoring of depressive illness prevalence and its risk factors, which will inform the development of effective interventions and policies aimed at mitigating this mental health issue.

The emerging role of regulatory T cells in the immunopathogenesis of vitiligo and implications for treatment.

Vitiligo is an autoimmune skin disease that targets pigment-producing melanocytes and results in depigmentation. This disfiguring condition frequently affects visible areas of the body and therefore causes a heavy psychological burden and a decreased quality of life. Although remains intractable, the evergrowing understanding of its immunopathogenesis has dramatically shaped the treatment paradigm for vitiligo. With the impact of autoreactive cytotoxic T cells explained extensively, accumulating evidence suggests the unique role of regulatory T (Treg) cells in the immune microenvironment of vitiligo. We systematically reviewed Treg deficiency, instability, reduced vitality and dysfunction reported in vitiligo patients, combined with novel findings regarding Treg function modulation in autoimmune backgrounds including metabolic alteration, post-translational modifications and interaction with other immune cells. We further summarized classic and advanced Treg-targeted therapeutics in vitiligo practice and research. Herein, we aimed to display the updated knowledge of Treg cells in vitiligo, providing insights into novel Treg-based therapeutic strategies.

Unraveling Vitiligo: From Immune Mechanisms to Promising Therapeutic Strategies

Vitiligo is a dermatological condition affecting 1% of the global population, characterized by the loss of skin pigmentation. It appears in two main forms: nonsegmental (symmetrical depigmentation) and segmental (localized depigmentation). Oxidative stress and mitochondrial dysfunction in melanocytes cause vitiligo, while immune privilege protects hair follicle melanocytes, allowing for possible repigmentation. Genetic factors and associations with other autoimmune diseases, such as type 1 diabetes and thyroiditis, suggest a heritable autoimmune component. CD8+ T cells play a crucial role in vitiligo, targeting melanocytes and promoting apoptosis. These cells, along with IFN-γ signaling, contribute to disease progression. Therapies targeting these pathways, such as JAK inhibitors, have shown promise in repigmentation, particularly when combined with narrowband UVB phototherapy, a gold standard treatment. Surgical interventions, including punch grafting and suction blister grafting, show high efficiency but bring high risks of skin damage and hyperpigmentation. Vitiligo patients experience significant emotional suffering, requiring both a psychological and medical treatment approach. Dietary interventions, specifically those rich in antioxidants, may support disease treatment. Vitamin D, in particular, is a promising therapeutic agent by protecting melanocytes from oxidative stress via the WNT/β-catenin pathway. This review points out the need for more research on targeted therapies that combine immune regulation, phototherapy, and dietary strategies for effective vitiligo treatment.

Assessment of Efficacy on the Treatment of Localized Vitiligo With a Combination of 308 nm Excimer Light and 2940 Erbium Laser: A Retrospective Study.

A 308 nm excimer light is an effective treatment for vitiligo, with fewer treatment times, rapid obvious effects, relatively complete pigment recovery, good patient compliance, and safe and effective treatment for children. The disadvantage of this treatment is that some patients have a plateau during which the skin lesion reduction rate slows down or stalls after multiple treatments. Treatment data were collected from all vitiligo patients in the Dermatology Department, distinguishing between those who underwent 308 nm excimer light treatment alone and those who received a combination of 308 nm excimer light and 2940 erbium laser treatment. Of the 104 patients, 60 were treated with 308 nm excimer light only, and 44 were treated with a combination of a 2940 erbium laser and 308 nm excimer light. In contrast to the treatment of 308 nm excimer light alone, the combined treatment of the 2940 erbium laser and 308 nm excimer light significantly increased the speed and degree of repigmentation in vitiligo. Our study demonstrates that the combination of 308 nm excimer light and 2940 nm erbium laser treatment can improve the treatment response for vitiligo, decrease the occurrence of treatment plateaus associated with 308 nm excimer light, and improve efficacy. ChiCTR2000036712 (24/08/2020).

A COMPARATIVE STUDY OF ORAL PSORALEN VS METHYLPREDNISOLONE WITH NARROW BAND UVB THERAPY IN VITILIGO

Objective: The efficacy and safety evaluation of oral Psoralen and of oral Methylprednisolone along with narrow-band ultraviolet B (NB-UVB). To observe the safety and efficacy of oral Psoralen in patients of Vitiligo. To observe the safety and efficacy of oral Methylprednisolone along with NB-UVB in patients of Vitiligo. To compare the safety and efficacy of oral Psoralen and oral Methylprednisolone along with NB-UVB during the study. To assess the dermatological life quality index (DLQI) in patients of Vitiligo before, during treatment, and after treatment. Methodology: A randomized controlled trial was conducted involving 76 patients diagnosed with generalized vitiligo. Patients were randomly assigned to either Group A or Group B. Group A received oral psoralen (0.3–0.6 mg/kg) followed by Twice-weekly sessions of NB-UVB therapy along with methylprednisolone. Results: As per the observations, the DLQI of the patients treated with the methylprednisolone with NB-UVB were showing better results as compared to the oral psoralen group. Conclusion: Even though vitiligo does not pose a direct threat to a person’s physical or mental health, it does cause a great deal of suffering for those who suffer from it and their loved ones. Therefore, treatment is necessary. While there are a number of systemic and topical treatments for this condition, phototherapy – and particularly NB-UVB – is among the most effective and safest options.

Retinal Vascular Changes in Vitiligo: A Novel Approach Using OCTA

ABSTRACT Purpose This study aimed to the detect of structural and functional changes in the retina and choroid in patients with vitiligo using optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA). Materials and Methods Thirty patients with vitiligo and 30 healthy participants were enrolled in the study. Central macular thickness (CMT), retina nerve fiber layer (RNFL) thickness, choroidal thickness (CT), foveal avascular zone (FAZ) area, and superficial and deep vascular density (VD) ratios were compared between the groups. Results The mean age was 43.32 ± 12.13 and 45.90 ± 7.50 years, respectively (p = 0.435). CMT, RNFL thicknesses (except temporal quadrant), CT, superficial and deep VD, and FAZ area were similar between the two groups (p > 0.05 for all). Temporal RNFL thicknesses were lower in vitiligo patients than in control groups (p = 0.005). There was a moderate negative correlation between the duration of vitiligo disease and the mean RNFL thickness, inferior RNFL thickness, superficial total, superior, superior inner, outer, and superior outer VD values. No correlation was found between the VASI (Vitiligo area scoring index) score in vitiligo patients and OCT and OCTA values. Conclusion Although it is known that vitiligo causes melanocyte loss in ocular tissues, there was no significant effect of vitiligo on superficial and deep retinal VD. Further comprehensive studies with a larger and more diverse population of vitiligo patients are needed to explore this further.

INVESTIGATING THE ROLE OF B-CELL ACTIVATING FACTOR (BAFF), GALECTIN-9, AND CD73 IN THE PATHOGENESIS OF VITILIGO: A CORRELATIVE STUDY WITH BIOCHEMICAL FACTORS

Objective: To investigate the involvement of immune-regulatory molecules—B-cell Activating Factor (BAFF), Galectin-9, and CD73—in the pathogenesis of vitiligo. Methods: A case-control study involving 50 patients with active vitiligo and 50 healthy controls. Peripheral blood and skin biopsy samples were collected to measure the concentrations of BAFF, Galectin-9, and CD73. Statistical analysis was conducted to evaluate differences and correlations between these markers. Results: The results showed that the levels of B-cell Activating Factor (BAFF) were significantly higher in vitiligo patients (150.64 ng/mL) compared to healthy controls (85.16 ng/mL). Similarly, Galectin-9 concentrations were elevated in patients (203.02 ng/mL) relative to controls (149.68 ng/mL). In contrast, CD73 levels were lower in vitiligo patients (49.66 ng/mL) compared to healthy controls (79.37 ng/mL), although this difference was not statistically significant. Correlation analysis revealed a positive association between BAFF and Galectin-9, while CD73 exhibited a negative correlation with both BAFF and Galectin-9. Novelty: The study identifies BAFF and Galectin-9 as potential biomarkers for vitiligo severity and suggests CD73 as a modulator of immune responses. This adds new insights into the immunopathology of vitiligo and highlights potential therapeutic targets

Evaluating Cancer Risk in a Large Cohort of 25,008 Vitiligo Patients: Insights from a Comprehensive Cohort Population-Based Study

BackgroundCurrent research presents inconsistent results concerning the incidence of various malignancies among patients with vitiligo. ObjectivesTo evaluate the risk for cancer in patients with vitiligo. MethodsA population-based study was conducted using Clalit Health Services database (2000-2023) using a cohort study design. Adjusted hazard ratios (HR) were calculated by multivariate Cox regressions. ResultsThe study included 25,008 patients with vitiligo and 245,550 matched controls. The mean (SD) age of patients with vitiligo was 35.96 (22.39) years; 12,679 (50.70%) patients were male. There were 499 (95% CI 468-532) and 487 (95% CI 476-497) incident cancer cases per 100,000 person-years among patients with vitiligo and without, respectively (adjusted HR 1.00; 95% CI 0.93-1.07; p=0.999). Patients with vitiligo had a reduced risk of melanoma (adjusted HR 0.70; 95% CI 0.50-0.99; p=0.0337), lung cancer (adjusted HR 0.73; 95% CI 0.57-0.93; p=0.007) and bladder cancer (adjusted HR 0.70; 95% CI 0.52-0.94; p=0.0138). LimitationsThe secondary analysis involved multiple comparisons, which could potentially influence the results. ConclusionOur study found that cancer incidence rates in patients with vitiligo are not elevated. Consequently, cancer screening for these patients should follow the standard guidelines recommended for the general population.

The psychosocial impact of pediatric vitiligo, psoriasis, eczema, and alopecia: A systematic review

This review focuses on chronic pediatric skin conditions—vitiligo, psoriasis, alopecia, and eczema—and their profound psychosocial impact on children and adolescents. Currently, a comprehensive comparative analysis across these conditions is absent, and comparisons between diverse psychosocial measures are lacking. This review aims to bridge that gap through a systematic review analyzing studies from PubMed and Embase up to April 2023 according to PRISMA. The findings emphasize that psoriasis and vitiligo significantly diminish the quality of life (QoL) of young individuals, heightening their risk for concurrent mental health issues. Eczema also reduces QoL, while alopecia increases vulnerability to anxiety and depression. Severity of psoriasis, vitiligo, and eczema correlates with worsened QoL, but longer disease duration leads to better physical functioning. Effective interventions identified include UVB light treatment and virtual support groups, notably improving vitiligo patients’ QoL, while psychologist consultations enhance self-image and psychological well-being in those with psoriasis and eczema.

Combination Therapy with Baricitinib and Narrowband Ultraviolet B for Active Non-Segmental Vitiligo: A Retrospective Controlled Study.

Vitiligo is a chronic autoimmune disease manifested by depigmented patches of skin devoid of melanocytes. Baricitinib, a JAK inhibitor selectively targeting JAK1/2, has shown preliminary efficacy for vitiligo. We aimed to assess the efficacy and tolerability of combination therapy with baricitinib and narrowband UV-B (NB-UVB) to treat active nonsegmental vitiligo (NSV). We formed a combination group of 52 patients with NSV receiving baricitinib and NB-UVB irradiation, and a control group of 49 patients with NSV receiving oral mini-pulse (OMP) methylprednisolone and NB-UVB irradiation. Efficacy analysis was conducted for the 6-month period. Six months after the last treatment, the recurrence rates were investigated through follow-up. From the first month, the mean total vitiligo area scoring index (VASI) score was significantly reduced in the combination group when compared to that in the control group. Starting on the fourth month, the overall response rates (ORRs) were significantly higher in the combination group than in the control group (P=0.034). By the sixth month, the ORRs reached 86.5% in the combination group, whereas they reached 67.3% in the control group (P=0.022). The serum levels of IFN-γ and CXCL10 in the combination group decreased from 38.52±5.98 pg/mL and 976.67±150.57 pg/mL at baseline to 26.46±5.93 pg/mL and 704.14±103.38 pg/mL at the 6-month juncture, respectively (P<0.001). Moreover, we found that there was no significant difference in recurrence rates within 6 months after stopping treatment in both groups. Three patients (5.8%) in the combination group reported developing itchy skin during the first month of treatment period, and one patient (1.9%) developed erythema; no other serious adverse events occurred. Our observations suggest that the combination therapy with baricitinib and NB-UVB is a promising strategy against NSV. Patients tolerated the treatment well without serious AEs, these results expand treatment options for vitiligo patients, warranting larger clinical trials.